Monogram Technologies Inc. has 2 Schedule 13D or 13G filings on record since 2025-07-15. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | 27% | 9,754,256 | SCHEDULE 13D, 2025-07-15 | 2025-07-11 |
| Icahn School Of Medicine At Mount Sinai | 5.8% | 2,360,304 | SCHEDULE 13G, 2025-07-18 | 2023-12-31 |
Purpose of Transaction (Item 4)
Zimmer Biomet Holdings, Inc.
The purpose of the Merger (as defined below) is for Parent, through Merger Sub, to acquire control of, and the entire equity interest in, the Company. On July 11, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Merger Sub. The Board of Directors of the Company (the "Board") has unanimously approved the Merger Agreement and the transactions contemplated thereby, including the Merger. Effect on Capital Stock The Merger Agreement provides that, subject to the terms and conditions set forth therein, at the effective time of the Merger (the "Effective Time"), (1) Merger Sub will be merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent, (2) each share of Common Stock issued and outstanding immediately prior to the Effective Time (other than shares owned by (i) the Company (or held in the Company's treasury), (ii) Parent, Merger Sub or any other direct or indirect wholly-owned subsidiary of Parent or Merger Sub or (iii) stockholders who have properly exercised and perfected appraisal rights under Delaware law) will be automatically cancelled and converted into the right to receive (A) $4.04 per share in cash, without interest and subject to applicable withholding taxes (the "Cash Amount"), plus (B) one contractual contingent value right per share representing the right to receive five contingent cash …The first part of Item 4 of the SCHEDULE 13D filed 2025-07-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-15 | Zimmer Biomet Holdings, Inc. | 27% | SCHEDULE 13D |
| 2025-07-18 | Icahn School Of Medicine At Mount Sinai | 5.8% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Monogram Technologies Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.